Loading
Spanish university hospital whose haematology department, home of María-Victoria Mateos and the Spanish Myeloma Group, led the trials that defined treatment of smouldering and newly diagnosed myeloma.
The University Hospital of Salamanca and its research institute IBSAL form one of Europe's leading myeloma centres. Its haematology department, long associated with Jesús San Miguel and now with María-Victoria Mateos, coordinates the Spanish Myeloma Group (GEM/PETHEMA) and led the trials of lenalidomide in high-risk smouldering myeloma, the ALCYONE trial of daratumumab in transplant-ineligible patients and the flow cytometry methods for measuring minimal residual disease.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Complejo Hospitalario de Salamanca, including child institutions. 408 works · 5,102 citations · 77% open access · 18% clinical trials · 1% reviews.
Shares María-Victoria Mateos, Multiple myeloma.
